Endocan as a marker of disease severity in pulmonary thromboembolism

Kuluöztürk, Mutlu; İn, Erdal; İlhan, Nevin

doi:10.1111/crj.13089

Cited by 10 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated in many pathologies such as atherosclerosis, diabetic vasculopathy, vascular invasion in malignancies and new vascular formation, vascular thrombosis, acute coronary syndrome, and pulmonary embolism. [3][4][5][6] Serum endocan levels are increased in diseases with vascular involvement or invasion. 25,26 A study showed that there was a significant correlation between endocan messenger RNA (mRNA) levels and intratumoral microvessel density, mRNA of vascular endothelial growth factor, and vascular or venous invasion.…”

Section: Discussionmentioning

confidence: 99%

Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study

et al. 2020

View full text Add to dashboard Cite

Thrombotic and embolic complications in the cardiovascular system are evident and associated with worse prognosis in coronavirus disease 2019 (COVID-19) patients. Endothelial-specific molecule 1 (endocan) plays a role in vascular pathology. We hypothesized serum endocan levels on admission are associated with primary composite end point (mortality and intensive care unit hospitalization) in COVID-19 patients. Patients (n = 80) with laboratory, clinical, and radiological confirmed COVID-19 were included in this cross-sectional study. Ten milliliter of peripheral venous blood were drawn within 24 hours of admission to estimate serum endocan levels. Data were analyzed using SPSS version 26.0 (IBM). Patients with the primary composite end point had significantly higher serum endocan levels than patients without (852.2 ± 522.7 vs 550.2 ± 440.8 ng/L, respectively; P < .01). In the logistic regression analysis, only increased serum endocan levels and increase in age were independent predictors of the primary composite end point ( P < .05). In the receiver operating characteristics curve analysis, we found that a serum endocan level of 276.4 ng/L had a 97% sensitivity and 85% specificity for prediction of the primary composite end point. Baseline serum endocan levels may prove useful as a prognostic factor in patients hospitalized for COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Two of those molecules are Endocan (Endothelial cell-Specific Molecule 1, ESM-1) and Lumican, but only few clinical studies address their applicability in NAFLD. The former is a proteoglycan well studied as an endothelial dysfunction biomarker in miscellaneous conditions like cancer, sepsis, pneumonia, pulmonary thromboembolism, chronic kidney disease, diabetes mellitus, preterm delivery-associated complications in neonates, and systemic sclerosis [6][7][8][9]. The latter is a small leucine-rich proteoglycan expressed in the extracellular matrix which regulates the process of collagen fibrillogenesis [10].…”

Section: Introductionmentioning

confidence: 99%

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Balanescu

Codreanu

Comanici

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors. We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O) patients. Ten healthy controls were recruited. Serum Lumican and Endocan levels were analyzed using ELISA kits. O&O patients had lower levels of Endocan compared to healthy controls (p<0.001). There were no differences between serum Endocan levels in O&O patients with NAFLD and those without (p=0.53). Patients considered having Nonalcoholic Steatohepatitis (NASH) had lower Endocan levels compared to O&O patients without NASH (p=0.026). Patients with metabolic syndrome had lower levels of Endocan (p=0.003). There were no significant differences between serum Lumican levels in O&O children compared to healthy controls. Lumican levels were higher in patients with hypertension (p=0.04). In O&O patients, Lumican levels were negatively correlated with Endocan levels (r=−0.37, p=0.002). Endocan seems a promising biomarker for the evaluation of pediatric NASH. Lumican was not confirmed as a biomarker for NAFLD in our cohort but was associated with higher arterial pressure. Low Endocan levels are accompanied by high serum Lumican levels, and this could be an early signature of cardiometabolic risk.

show abstract

“…Destruction of glycocalyx results in the loss of heparan sulfate and exposure on the surface of endothelial cells of adhesion molecules inter-cellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1), which become accessible for circulating leukocytes involved in thrombosis [ 50 , 51 ]. One of the components of glycocalyx is the proteoglycan endocan [ 52 ]. Thus, expression of endocan is specific to the endothelium of the pulmonary and renal arteries [ 52 ].…”

Section: Potential Mechanisms For Primary Thrombosis In the Pamentioning

confidence: 99%

“…One of the components of glycocalyx is the proteoglycan endocan [ 52 ]. Thus, expression of endocan is specific to the endothelium of the pulmonary and renal arteries [ 52 ]. Increase in blood endocan levels in patients with CT angiographic evidence of a pulmonary thrombotic event is associated with a more severe course of the disease [ 52 ].…”

Section: Potential Mechanisms For Primary Thrombosis In the Pamentioning

confidence: 99%

“…Thus, expression of endocan is specific to the endothelium of the pulmonary and renal arteries [ 52 ]. Increase in blood endocan levels in patients with CT angiographic evidence of a pulmonary thrombotic event is associated with a more severe course of the disease [ 52 ]. Blood endocan levels rise with increased PA pressure and decreased partial oxygen tension.…”

Section: Potential Mechanisms For Primary Thrombosis In the Pamentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Artery Thrombosis: A Diagnosis That Strives for Its Independence

Porembskaya

Toropova

Tomson

et al. 2020

IJMS

View full text Add to dashboard Cite

According to a widespread theory, thrombotic masses are not formed in the pulmonary artery (PA) but result from migration of blood clots from the venous system. This concept has prevailed in clinical practice for more than a century. However, a new technologic era has brought forth more diagnostic possibilities, and it has been shown that thrombotic masses in the PA could, in many cases, be found without any obvious source of emboli. Chronic obstructive pulmonary disease, asthma, sickle cell anemia, emergency and elective surgery, viral pneumonia, and other conditions could be complicated by PA thrombosis development without concomitant deep vein thrombosis (DVT). Different pathologies have different causes for local PA thrombotic process. As evidenced by experimental results and clinical observations, endothelial and platelet activation are the crucial mechanisms of this process. Endothelial dysfunction can impair antithrombotic function of the arterial wall through downregulation of endothelial nitric oxide synthase (eNOS) or via stimulation of adhesion receptor expression. Hypoxia, proinflammatory cytokines, or genetic mutations may underlie the procoagulant phenotype of the PA endothelium. Both endotheliocytes and platelets could be activated by protease mediated receptor (PAR)- and receptors for advanced glycation end (RAGE)-dependent mechanisms. Hypoxia, in particular induced by high altitudes, could play a role in thrombotic complications as a trigger of platelet activity. In this review, we discuss potential mechanisms of PA thrombosis in situ.

show abstract

Endocan as a marker of disease severity in pulmonary thromboembolism

Cited by 10 publications

References 33 publications

Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study

Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Pulmonary Artery Thrombosis: A Diagnosis That Strives for Its Independence

Contact Info

Product

Resources

About